Comparative Pharmacology
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus CYCLOSET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus CYCLOSET.
BROMOCRIPTINE MESYLATE vs CYCLOSET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist / Antidiabetic